Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.51 |
| ▸ | FABP7 | O15540 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68446 | 0.85 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL24616691 | 0.82 | HCAR2 (0.53) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL15304743 | 0.82 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29396065 | 0.82 | HCAR2 (0.53) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL9081038 | 0.82 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL16586266 | 0.82 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL15981181 | 0.82 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL44676 | 0.82 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL9078154 | 0.82 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30792907 | 0.81 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240094120-A1 | Control Of N-(Phosphonomethyl) Iminodiacetic Acid Conversion In Manufacture Of Glyphosate | MONSANTO TECHNOLOGY LLC | 2024-03-21 | — | — | US | disclosed |
| US-11802835-B2 | Control of N-(phosphonomethyl)iminodiacetic acid conversion manufacture of glyphosate | MONSANTO TECHNOLOGY LLC (US) | 2023-10-31 | — | — | US | disclosed |
| CN-104684576-B | PEGylated OXM variants | 奥普科生物制品有限公司 | 2019-08-06 | — | — | CN | disclosed |
| CN-109096387-A | The OXM variant of Pegylation | 奥普科生物制品有限公司 | 2018-12-28 | — | — | CN | disclosed |
| CN-108064253-A | Polymer matrices formed from carboxy-functional acrylamides | 生命技术公司 | 2018-05-22 | — | — | CN | disclosed |
| CN-104877014-B | A kind of method of purifying Te Lawan star crude products | 宁夏泰瑞制药股份有限公司 | 2018-05-11 | — | — | CN | disclosed |
| CN-104583382-B | Laundry soap bar | 诺维信公司 | 2017-10-20 | — | — | CN | disclosed |
| CN-106994126-A | Use the therapeutic scheme of various medicaments | 因特利凯有限责任公司 | 2017-08-01 | — | — | CN | disclosed |
| CN-106924741-A | Use the therapeutic scheme of various medicaments | 因特利凯有限责任公司 | 2017-07-07 | — | — | CN | disclosed |
| CN-103703174-B | Combination pharmaceutical compositions and uses thereof | 因特利凯有限责任公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-106220623-A | Compounds and methods for and indication thereof for kinases regulation | 普莱希科公司 | 2016-12-14 | — | — | CN | disclosed |
| CN-103491962-B | Combinations of kinase inhibitors and uses thereof | 因特利凯有限责任公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-1328571-B | The human monoclonal antibodies of anti-CTLA-4 | 辉瑞大药厂 | 2016-08-31 | — | — | CN | disclosed |
| CN-105906631-A | Compounds and methods for kinase modulation, and indications therefor | 普莱希科公司 | 2016-08-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802835-B2 | Control of N-(phosphonomethyl)iminodiacetic acid conversion manufacture of glyphosate | GNMT, GMNN, PTMS | KMT2A 783/4885FABP5 1840/4885FABP7 3223/4885 |
| US-20240094120-A1 | Control Of N-(Phosphonomethyl) Iminodiacetic Acid Conversion In Manufacture Of Glyphosate | GNMT, GMNN, PTMS | KMT2A 695/4885FABP5 1896/4885FABP7 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.